Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
On 20 and 24 November 2019, respectively, the Dutch public health authorities confirmed two imported cases of Lassa fever from Sierra Leone. Both were Dutch healthcare workers who worked in a rural hospital in Sierra Leone.
This document assesses the risk to human health posed by a multi-country incident of botulism neurotoxin type E, possibly associated with consumption of a commercially-available dried and salted fish product.
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
At the request of the European Commission, ECDC performed a risk assessment after six cases of wound botulism were reported in Norway among people who had injected heroin. As this is an ongoing problem, some relevant measures are proposed for consideration by other EU/EEA Member States.